KENNETH W. LYLES, M.D.; WILLIAM R. BERRY, M.D.; MARK HAUSSLER, Ph.D.; JOHN M. HARRELSON, M.D.; MARC K. DREZNER, M.D.
LYLES KW, BERRY WR, HAUSSLER M, HARRELSON JM, DREZNER MK. Hypophosphatemic Osteomalacia: Association with Prostatic Carcinoma. Ann Intern Med. 1980;93:275-278. doi: 10.7326/0003-4819-93-2-275
Download citation file:
Published: Ann Intern Med. 1980;93(2):275-278.
Hypophosphatemic osteomalacia that remits after resection of a coexisting tumor has been described in 35 patients. Because the associated neoplasms have been of mesenchymal origin, it has been inferred that this tumorinduced osteomalacia syndrome is uniquely related to tumors of this derivation. However, in the present investigation we studied subjects with coincident hypophosphatemia and prostatic carcinoma to ascertain whether this endodermal malignancy causes the tumor-induced osteomalacia syndrome. The hypophosphatemic patients had renal phosphate wasting, gastrointestinal malabsorption of calcium and phosphate, and negative phosphate balance. Moreover, bone biopsies showed histomorphologic changes indicative of osteomalacia. Although widespread metastases precluded establishing the diagnosis of tumor-induced osteomalacia by resection of the tumor, a series of studies excluded alternate causes for the osteomalacia. Further, affected subjects had a normal serum concentration of 2 5-hydroxy vitamin D, 28.0 ± 8.3 ng/mL, and serum 1,25-dihydroxyvitamin D levels were low, 15.0 ± 1.0 pg/mL, characteristic of the tumor-induced osteomalacia syndrome. Thus, prostatic carcinoma, although an endodermal malignancy, may cause the tumor-induced osteomalacia syndrome.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Hematology/Oncology, Metabolic Bone Disorders.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only